ABT-378: Abbott "second generation" protease inhibitor
- PMID: 11364243
ABT-378: Abbott "second generation" protease inhibitor
Abstract
AIDS: Abbott Laboratories has released the first public data on ABT-378, a new generation protease inhibitor that is designed to be effective even against protease inhibitor-resistant HIV. ABT-378 is active against viruses that are resistant to ritonavir and indinavir. Early tests indicate that combining the drug with a fraction of the usual dose of ritonavir delays the body's destruction of the drug, and it may only require one or two daily doses. No human testing has been done.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical